Rapport Therapeutics
- Market cap
- 1.48B
- P/E (TTM)i
- -10.18
- P/Bi
- 3.50
- EPSi
- -2.86
- Div yieldi
- 0.00%
- 52W posi
- 24%
Anonymous reader poll. Unscientific, not investment advice.
Rapport Therapeutics ended the session at 30.86, down 0.93%. The company carries a market value of roughly 1.48B, the #2970 most valuable US-listed company we track. Wall Street's 9-analyst consensus lands on Buy, with a price target averaging 61.80 (+100% from here). Over the past year the stock has ranged from 23.75 to 52.93; it now sits 24% up that band.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Recent price momentum is -2.8% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 4.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -28.2% | Better than 5% |
| Return on invested capital | -31.2% | Better than 3% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -19.0% | Better than 12% |
| 6-month return | -3.9% | Better than 32% |
| 12-month return (ex latest month) | 65.0% | Better than 87% |
| Distance below 52-week high | 39.2% | Better than 15% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 26.2x | Better than 100% |
| Debt to assets | 2.2% | Better than 92% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 92.0% | Better than 95% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 31.15
- Open
- 30.81
- Day range
- 30.46 - 31.35
- Avg price
- 30.91
- Volume
- 314.99K
- Turnover
- 9.74M
- Turnover ratei
- 1.04%
- Volume ratioi
- 0.97
- Amplitudei
- 2.87%
- 52-week rangei
- 23.75 - 52.93
Valuation
- P/Ei
- -10.79
- P/E (TTM)i
- -10.18
- P/Bi
- 3.50
- EPSi
- -2.86
- Book value / shi
- 8.82
- Net profit
- -137.22M
- Net assets
- 422.93M
Share structure
- Market cap
- 1.48B
- Float capi
- 937.95M
- Shares out
- 47.98M
- Float sharesi
- 30.39M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2024-06-07
41.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+1.27M net over the window
Short interest
- Shares short
- 2.25M
- % of floati
- 4.69%
- Days to coveri
- 7.91
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Rapport Therapeutics (RAPP)?
Rapport Therapeutics last traded at 30.86. The quote on this page refreshes every few seconds while US markets are open.
What is Rapport Therapeutics's market cap?
About 1.48B.
What is the P/E ratio of Rapport Therapeutics?
The trailing twelve-month P/E is -10.18. The Valuation tab shows it against the stock's own five-year range.
Does Rapport Therapeutics pay a dividend?
Rapport Therapeutics does not currently pay a regular dividend.
Is Rapport Therapeutics a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 61.80, which implies 100.3% upside from the current price. This is not investment advice.
What is Rapport Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Rapport Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 07:00:02 · For reference only, not investment advice and not tailored to your situation.